KU-55933: Potent ATM Kinase Inhibitor for DNA Damage Resp...
KU-55933: Potent ATM Kinase Inhibitor for DNA Damage Response Research
Principle and Setup: Targeted Inhibition of ATM Signaling Pathways
KU-55933 is recognized as a potent and highly selective ATM kinase inhibitor, uniquely suited for DNA damage response research, cancer biology, and translational studies. With an impressive IC50 of 13 nM and a Ki of 2.2 nM, KU-55933 demonstrates specificity against ATM kinase, sparing related kinases such as DNA-PK, PI3K/PI4K, ATR, and mTOR. ATM kinase orchestrates cellular responses to DNA double-strand breaks by phosphorylating downstream effectors, notably modulating the Akt phosphorylation pathway at Ser473. Disruption of this signaling through ATM inhibition provides a powerful tool to probe DNA damage checkpoint signaling, cell cycle arrest induction, and cancer cell proliferation inhibition.
Sourced from APExBIO, KU-55933 (ATM Kinase Inhibitor) is supplied as a solid, easily dissolved in DMSO (≥41.67 mg/mL with gentle warming), but insoluble in water and ethanol. For optimal experimental consistency, it is recommended to store the desiccated compound at –20°C and to prepare fresh working solutions, as prolonged storage of solutions is not advised.
Step-by-Step Workflow: Protocol Enhancements for Reliable Results
1. Preparation and Handling
- Stock Solution: Dissolve KU-55933 in DMSO at a concentration of 10–20 mM. Warm gently if needed to facilitate dissolution. Aliquot and store at –20°C to avoid repeated freeze-thaw cycles.
- Working Solution: Dilute the stock to the desired final concentration (commonly 1–10 μM) in cell culture medium. Ensure the final DMSO concentration does not exceed 0.1% to minimize cytotoxicity.
2. Experimental Workflow
- Cell Seeding: Plate cells (e.g., cancer cell lines such as MDA-MB-453, PC-3, or iPSC-derived models) at densities optimized for the endpoint assay (proliferation, DNA damage, metabolism).
- Treatment: Add KU-55933 at the chosen concentration. For ATM signaling studies, pre-treat for 30–60 min prior to DNA damage induction (e.g., ionizing radiation or genotoxic drugs).
-
Readouts:
- For ATM activity: Immunoblotting for phospho-Akt (Ser473), γH2AX, or downstream checkpoint proteins.
- For cell cycle: Flow cytometry for G1/G2/M distribution.
- For metabolic profiling: Lactate, ATP, and glucose assays.
- Controls: Include DMSO vehicle controls, positive controls (DNA-PK or ATR inhibitors), and untreated groups for robust interpretation.
3. Protocol Enhancements
- To maximize ATM pathway suppression, stagger DNA damage induction and KU-55933 addition based on your cell line's kinetics.
- For iPSC-derived models, as shown in the Sequiera et al. Science Advances study, titrate KU-55933 concentrations to balance efficacy and cytotoxicity unique to patient-specific lines.
Advanced Applications: Expanding the Frontier of ATM Inhibition
iPSC-Based Disease Modeling and Personalized Medicine
KU-55933's selectivity for ATM makes it a cornerstone for iPSC-based disease platforms, particularly for dissecting the functional consequences of rare DNA repair defects or ultrarare genetic mutations. In the landmark Sequiera et al. study, an iPSC-based platform enabled high-content drug screening for a patient with Leigh-like syndrome, an ultrarare mitochondrial disorder. Such workflows benefit from ATM inhibition to study DNA damage checkpoint signaling and metabolic repercussions, providing actionable insights for prescreening and clinical decision-making in personalized medicine.
Cancer Cell Proliferation and Cell Cycle Arrest
In cancer research, KU-55933 is deployed to investigate ATM's role in tumor cell survival and proliferation. At 10 μM, KU-55933 induces approximately 50% inhibition of proliferation in MDA-MB-453 and PC-3 cancer cells, correlating with robust inhibition of ATM-mediated Akt phosphorylation and pronounced G1 cell cycle arrest via cyclin D1 downregulation (see detailed mechanism). These effects are quantifiable through cell viability assays and flow cytometry, lending translational relevance for preclinical drug discovery pipelines.
Metabolic Reprogramming and Genome Stability
KU-55933's inhibition of ATM also impacts cellular metabolism, as evidenced by increased lactate production, higher glucose consumption, and reduced ATP levels in MCF-7 cells. This establishes the compound as a dual-utility probe for both genome instability and metabolic vulnerabilities in cancer models—key for integrated omics studies (complementary metabolic insights).
Comparative Intelligence and Inter-article Integration
- KU-55933: Potent ATM Kinase Inhibitor for DNA Damage Resp... complements this protocol by providing advanced workflows for iPSC-based modeling and highlights troubleshooting strategies to maximize reproducibility.
- ATM Kinase Inhibitor Unveils New Frontiers in Genome Stability extends the scope by exploring emerging cGAS-driven mechanisms and ATM's intersection with innate immunity.
- Strategic Guidance for ATM Inhibitor Use offers a translational roadmap, contextualizing ATM inhibition in both cancer and ultrarare disease research, and synthesizes mechanistic with actionable guidance.
Troubleshooting and Optimization Tips
Ensuring Compound Integrity and Biological Activity
- Solubility Issues: If KU-55933 does not dissolve fully in DMSO, apply gentle warming (<40°C) and vortexing. Avoid sonication, which may degrade the compound.
- Storage: Always store lyophilized powder desiccated at –20°C. Stock solutions are stable for several months below –20°C, but working solutions should be used immediately.
- Precipitation in Medium: Add KU-55933 to medium just before use; minimize time in aqueous solution and confirm no visible precipitate forms. Filter-sterilize if necessary.
Experimental Design Considerations
- Concentration Titration: Optimal effective concentrations may vary between cell types; perform a pilot dose-response experiment (e.g., 0.1–20 μM) to identify the minimum dose for maximal ATM inhibition without off-target toxicity.
- Off-target Effects: Although highly selective, at higher concentrations, off-target inhibition of related kinases may occur. Include appropriate kinase activity assays to confirm ATM specificity in your system.
- Timing: ATM pathway kinetics can differ by cell type and DNA damage inducer; perform time-course studies (15 min to 6 h) to capture peak pathway modulation.
- Readout Optimization: Use phospho-specific antibodies validated for ATM targets (e.g., phospho-Akt Ser473, γH2AX) and include loading controls.
Case Study: Application in iPSC Models
In the Science Advances iPSC study, troubleshooting included careful optimization of KU-55933 dosing to avoid cytotoxicity in patient-derived iPSC lines. It's recommended to begin with lower doses (0.5–1 μM) and scale up as needed while monitoring viability and marker expression.
Future Outlook: ATM Inhibition and Personalized Genomics
The landscape of ATM kinase inhibitor research is rapidly evolving. With the advent of iPSC-based disease modeling, the ability to simulate patient-specific responses to DNA damage and metabolic stressors is transforming both basic and translational research. KU-55933, as supplied by APExBIO, is poised to remain a staple reagent in these workflows, underpinning advances in DNA damage checkpoint signaling, the Akt pathway, and metabolic reprogramming. Future innovations may include high-throughput iPSC-drug screening platforms for ultrarare diseases, as exemplified by the personalized approach in Sequiera et al., 2022, and integration with multi-omics profiling to unravel complex ATM-dependent networks.
In summary: KU-55933 (ATM Kinase Inhibitor) stands as a benchmark tool for dissecting ATM signaling pathways, enabling precise manipulation of cell cycle, proliferation, and metabolism in cancer and disease models. By following optimized protocols and troubleshooting effectively, researchers can unlock new dimensions in DNA damage response research and pave the way for personalized therapeutic strategies.